Free Trial
Earnings Season Is Here. MarketBeat All Access for Just $149
  • 0Days
  • 0Hours
  • 0Minutes
  • 0Seconds
Get the Deal
Claim MarketBeat All Access Sale Promotion
NASDAQ:PRPH

ProPhase Labs Q3 2026 Earnings Date & Estimates

ProPhase Labs logo
$0.0091 +0.00 (+1.11%)
As of 10:42 AM Eastern

ProPhase Labs is estimated to report Q3 2026 earnings on Monday, November 16, 2026. The conference call is scheduled for November 18, 2026 at 2:00 PM ET.

Research:ProfileEarnings History

Upcoming Earnings Announcement

Quarter
Q3 2026
Announcement Date
Conference Call Date
Conference Call
2:00 PM ET
Google Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab)

What Analysts Expect from ProPhase Labs in Q3 2026

ProPhase Labs is expected to post earnings of $2.05 per share on revenue of $11.98 million. In the same quarter a year earlier ProPhase Labs reported -$1.60 per share on revenue of $883 thousand. ProPhase Labs last reported on November 19, 2025, posting -$1.60 per share and missing the -$1.10 consensus estimate. ProPhase Labs has beaten the consensus EPS estimate in 4 of its last 8 quarters.

Consensus Estimates

Consensus EPS
$2.05
Expected Revenue
$11.98 million
Prior-Year EPS
-$1.60
Prior-Year Revenue
$883 thousand
Expected Revenue Growth
+1,256.3%

Recent Track Record

Last Reported
Q3 2025
Last Quarter EPS
-$1.60 (Missed by -$0.50)
Last Quarter Revenue
$883 thousand
EPS Beat Rate
4 of last 8 quarters

Prepare for the Q3 2026 Call

ProPhase Labs Q3 2026 Earnings FAQ

ProPhase Labs (NASDAQ:PRPH) is estimated to report Q3 2026 earnings on Monday, November 16, 2026. This date is estimated from past reporting schedules and may change once the company confirms it.

ProPhase Labs' Q3 2026 earnings conference call is scheduled for Wednesday, November 18, 2026 at 2:00 PM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date.

Analysts expect ProPhase Labs to post earnings of $2.05 per share for Q3 2026.

The consensus revenue estimate for ProPhase Labs is $11.98 million for Q3 2026.

ProPhase Labs' next earnings date is estimated for Thursday, November 5, 2026. MarketBeat tracks confirmed and estimated earnings dates for ProPhase Labs on the company's earnings history page.

ProPhase Labs Earnings Headlines

ProPhase Labs Delays Quarterly SEC Filing
August 14, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/prophase-labs-delays-quarterly-sec-filing?utm_source=marketbeat.com&utm_medium=referral
ProPhase Labs Inc.
July 16, 2026  |  marketwatch.comhttps://www.marketwatch.com/investing/stock/prph/financials/cash-flow
Financial legend: “This is bad, really bad...”
Dr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each warning issued before the crisis hit. Now the founder of Weiss Ratings, the only conflict-free rating agency in America, says he is watching a $3 trillion problem that could trigger a chain reaction across markets and banks.tc pixel
October 28 at 1:00 AM  |  Weiss Ratings (Ad)
ProPhase Labs Announces Immediate Resignation of Board Member
June 25, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/PRPH/pressreleases/36984840/prophase-labs-announces-immediate-resignation-of-board-member/
ProPhase Labs Delays Quarterly Financial Filing
May 15, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/prophase-labs-delays-quarterly-financial-filing?utm_source=marketbeat.com&utm_medium=referral
ProPhase Labs Reports Year-End 2025 Results, Highlights Accelerating Settlement Activity and Investment-Ready Crown Medical Collections Platform
April 15, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/04/15/3274530/0/en/prophase-labs-reports-year-end-2025-results-highlights-accelerating-settlement-activity-and-investment-ready-crown-medical-collections-platform.html
See More ProPhase Labs Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like ProPhase Labs? Sign up for Earnings360's daily newsletter to receive timely earnings updates on ProPhase Labs and other key companies, straight to your email.

About ProPhase Labs

ProPhase Labs (NASDAQ:PRPH) is a diversified health and wellness company that develops and commercializes consumer health products, diagnostic services and genomic information solutions. The company’s activities have included over-the-counter products, laboratory testing and technologies designed to support personalized health and wellness.

ProPhase Labs is known for Cold-EEZE zinc products, including lozenges and other cold-related remedies. Through its diagnostic operations, the company has provided molecular testing and related laboratory services, including testing developed for infectious diseases. Its business has also included genomic services and data-focused offerings intended to help consumers better understand their genetic information.

The company was formerly known as The Quigley Corporation and adopted the ProPhase Labs name as it expanded beyond its traditional consumer healthcare business. ProPhase Labs is headquartered in Garden City, New York, and primarily serves the U.S. market through its consumer products, laboratory operations and health technology initiatives. Ted Karkus has served as the company’s chief executive officer.

View ProPhase Labs Profile
Earnings Tools